DMed provides contract clinical research services and will use the cash injection to hire additional assurance and clinical operations staff.
China-based contract clinical research services provider DMed has received $8m in a series A round that included biopharmaceutical company Zai Laboratory, China Money Network reported today.
The round was led by Qiming Venture Capital, with additional participation by Tairui Investment.
Founded in August 2016, DMed provides clinical research services to clients including Zai Laboratory and drug developer Hua Medicine. The money will support the recruitment of additional assurance and clinical operations staff.
Nisa Leung, managing partner at Qiming, said: “Established…
